Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint. The results are a landmark for Alnylam which has stuck doggedly ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

RNA interference (RNAi) therapeutics silence genes, disrupting the production of proteins that contribute to disease. Scientists at Alnylam Pharmaceuticals have developed and are testing multiple RNAi ...

A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $341.93, with a high estimate of $500.00 and a low estimate of $280.00. Marking an increase ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases. It has a strong catalog of approved products and a ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.